- The pharmaceutical CanSino Biologics Inc, developed and patented Convidecia Air, which is the first inhalable vaccine against Covid-19 in the world.
- It is based on the same intramuscular injection adenovirus vector technology platform from the same company.
- It is atomized into minute particles and then inhaled through the mouth, entering the human respiratory tract and lungs to induce a mucosal immune response, as well as humoral and cellular responses.
The world is about to celebrate three years since the start of the most serious health emergency of the last century. Throughout this period, more than 6.68 million deaths have been generated and the number continues to increase every day. While within the positive aspects is the development that the pharmaceutical industry has achieved. One of the most notable advances was achieved thanks to the first inhalable vaccine against Covid-19.
In this case, behind this invention is CanSino Biologics Inc. The company of Chinese origin surprised the world by unveiling the first batch of its new recombinant vaccine (type 5 adenovirus vector) for inhalation that has the Trade name of Convidia Air.
This alternative is useful for people who for various reasons are afraid of needles. It also facilitates vaccination campaigns because the process is simpler and allows more people to be protected in less time.
The first nation to authorize the emergency use of this biologic was China. While today it was announced that there is a second with which an agreement was reached and it is about Morocco. This seeks to provide an innovative solution to support and accelerate the construction of massive immune protection. This first batch of vaccines will be used as a booster dose.
Necessary doses and operation
In this case, Convidia Air works on a single-dose regimen using Aerogen’s proprietary aerosol drug delivery system. It is the world’s first inhaled COVID-19 vaccine, as well as being a non-invasive, painless and needle-free option delivered through a nebulizer.
The liquid vaccine is atomized into minute particles and then inhaled through the mouth, entering the human respiratory tract and lungs to induce a mucosal immune response, as well as humoral and cellular responses. Mucosal immunity is essential to form a first-line immune barrier that helps prevent virus invasion into the respiratory tract and prevent serious infections.
Clinical studies support the safety and efficacy profiles of CanSinoBIO’s inhaled COVID-19 vaccine. It is based on the same adenovirus vector technology platform as CanSinoBIO’s Convidecia delivered by intramuscular injection, but requiring only one-fifth the dose of the intramuscular version.
Booster with Convidecia Air after challenge with two doses of inactivated vaccines, the level of antibodies against the Omicron strain is 14 times higher than that of a homologous inactivated vaccine booster and 6 times higher than that of a protein vaccine booster heterologous recombinant on day 28 after booster vaccination.
Inhaled vaccine provides long-term protection
Meanwhile, 12 months after vaccination, levels of neutralizing antibodies against the parent COVID-19 strain and the Omicron variant remain significantly higher than those induced by a homologous inactivated vaccine booster, according to peer-reviewed research. published by Emerging Microbes & Infections in December 2022.
While Convidecia Air can be safely stored and transported in refrigeration facilities between 2°C and 8°C, which is more favorable in large-scale vaccination programs as it improves access to vaccines.
To date, this inhalable vaccine has been implemented in many provinces and municipalities in China, including Beijing, Tianjin, Shanghai, Jiangsu, Zhejiang, Shandong, Guangdong, Hainan, among others.
Also read:
CanSino’s Inhalant Vaccine Offers Protection Against the Omicron Variant
Finally! WHO approves emergency use of CanSino vaccine
AMLO demands that the WHO authorize the Sputnik V and Cansino vaccines